Hence, we believe these drugs may be potential chemotherapeutic agents to inhibit the malignant characteristics of CRC cells targeting ATP2A1. However, using these drugs in the clinical treatment of colorectal cancer needs more research to confirm and obtain permission for clinical treatment. This evidence concerns the gene ATP2A1 and colorectal carcinoma.